Soluble inhibitors of vascular endothelial growth factor and use thereof
AssigneeChildren's Medical Center Corporation
InventorsMichael Klagsbrun, Shay Soker, Michael L. Gagnon
Life of this patent
Estimating the term…
Abstract
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
Claims19
-26. (canceled)
An isolated cDNA encoding a human soluble neuropilin polypeptide which specifically binds VEGF165 and reduces VEGF-mediated HUVEC proliferation.
Dependencies are inferred from the claim text.